Skip to content
Peptide research

Apelin

Category
Muscle & Performance
Administration routes
Injectable
Regulatory status
Not FDA-approved

A naturally occurring peptide studied for cardiovascular and kidney effects, marketed by some clinics for anti-aging and muscle recovery. Human evidence supports blood pressure and blood flow effects, but anti-aging and muscle claims rest on animal and mechanistic work only. Its short half-life limits use, and liver enzyme elevations with the investigational small-molecule agonist azelaprag, preclinical tumor-angiogenesis findings, and blood-pressure effects remain concerns; these findings do not establish native apelin hepatotoxicity. Not FDA-approved; available mainly as unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Apelin is a naturally occurring peptide hormone produced throughout your body — especially in the heart, blood vessels, and muscles — that plays a central role in cardiovascular health, blood pressure regulation, and energy metabolism. It exists in several forms, the most potent being a 13-amino-acid version. Apelin gained particular attention in longevity research after a landmark 2018 Nature Medicine study identified it as an "exerkine" — a substance released during exercise — that declines with age and whose restoration reversed age-related muscle loss in mice.

How it works in the body

Binds to the APJ receptor found on heart muscle cells, blood vessels, and fat tissue. In the heart, it strengthens contractions and dilates blood vessels, lowering blood pressure. It also improves insulin sensitivity and helps regulate fluid balance through the kidneys.

Research overview

Apelin works by activating its receptor (APJ) on heart, blood vessel, kidney, and muscle cells, triggering vasodilation (widening of blood vessels), increased cardiac output, improved kidney function, and enhanced glucose and fat metabolism. It essentially acts as a natural counterbalance to the renin-angiotensin system that raises blood pressure. Human clinical studies — including randomized, placebo-controlled trials — have confirmed that apelin infusion reduces blood pressure, improves cardiac output, and increases renal blood flow in both healthy volunteers and patients with heart failure, pulmonary hypertension, and chronic kidney disease. A 2024 Nature Communications study in CKD patients showed it reduced proteinuria with kidney-protective effects similar to ACE inhibitors. For aging, the transformative 2018 Nature Medicine study showed that restoring apelin in aged mice reversed muscle wasting by reactivating mitochondrial production, cellular cleanup processes, and muscle stem cell regeneration. Over 3,000 publications exist on PubMed, but native apelin is limited by an extremely short half-life (under 8 minutes). Drug development efforts by Amgen, BioAge Labs, and Bristol-Myers Squibb have reached early clinical trials, though none have yet achieved approval — BioAge's oral version was discontinued in late 2024 due to liver enzyme elevations.

Who researches Apelin?

Commonly researched by

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

  • People researching respiratory health

    Studied for effects on lung function, bronchial health, or respiratory tissue.

Important considerations for

  • Those with Active cancer

    High

    Apelin promotes tumor angiogenesis, cancer cell proliferation, metastasis, and suppresses apoptosis across multiple cancer types.

  • Those with Hypotension

    Moderate

    Apelin causes vasodilation and reduces systemic blood pressure. Use caution in hypotensive states.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data. Apelin/APJ axis plays roles in placentation.

Safety & interactions

Do not use if

  • Active cancer

    High

    Apelin promotes tumor angiogenesis, cancer cell proliferation, metastasis, and suppresses apoptosis across multiple cancer types.

  • Hypotension

    Moderate

    Apelin causes vasodilation and reduces systemic blood pressure. Use caution in hypotensive states.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data. Apelin/APJ axis plays roles in placentation.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Extremely short plasma half-life limiting therapeutic utility

    High

    PMID 37956047 / PMC10757586 (Cardiovasc Res 2023 review); PMID 34385981 / PMC8359812

  • Potential hepatotoxicity with synthetic apelin receptor agonists

    Moderate

    BioAge Labs press release announcing STRIDES discontinuation, Dec 2024

  • Potential pro-tumorigenic effects via angiogenesis promotion

    Moderate

    PMID 32087570 (review); PMID 24962866 (apelin, lymphangiogenesis and lymph node metastasis)

  • Hypotension risk with acute administration

    Moderate

    PMID 20385929; PMID 29876530 / PMC5981010; PMID 39402039

  • Interaction with fluid balance and vasopressin regulation

    Moderate

    PMID 39402039; PMC8645901 (Front Endocrinol 2021); PMID 28620355 / PMC5450005

Interaction summary(8)

Rated by direction with this peptide

  • PDE5 inhibitors (sildenafil, tadalafil)

    SynergisticModerate

    In the randomized PAH crossover trial, the subgroup already taking a PDE5 inhibitor showed a substantially larger fall in pulmonary vascular resistance with apelin and larger cardiac output gains than those not on one, consistent with converging NO/cGMP signalling. This is a post-hoc, non-randomized subgroup comparison in roughly half of a 19-patient trial, so treat the magnitude as hypothesis-generating - but the direction is supported by human data, and the same convergence implies additive systemic vasodilation and blood pressure lowering.

    PMID 29876530 / PMC5981010

  • ACE inhibitors and ARBs (RAAS blockers)

    CautionLow

    Apelin counter-regulates angiotensin II and independently lowers systemic vascular resistance and mean arterial pressure, so additive hypotension is the expected pharmacodynamic result when layered onto RAAS blockade. Reassuringly, CKD patients in the 2024 crossover trial - most on background RAAS therapy - tolerated acute apelin infusion without serious adverse events. Low severity reflects predictable, monitorable additive vasodilation rather than any documented adverse interaction.

    PMID 39402039; PMID 37956047 / PMC10757586

  • Recombinant ACE2 and ACE2-modulating agents

    CautionTheoretical

    ACE2 hydrolyzes the C-terminal Pro-Phe bond of apelin-13, apelin-17 and apelin-36, removing the phenylalanine required for receptor activation. Raising ACE2 activity would therefore be expected to accelerate apelin clearance and blunt its effect, and reducing ACE2 activity to prolong it. This is established enzymology extrapolated to a drug pairing that has never been studied clinically - correctly labelled Theoretical.

    PMID 37956047 / PMC10757586

  • Neprilysin inhibitors (sacubitril/valsartan)

    SynergisticTheoretical

    Neprilysin is one of the proteases that degrades apelin peptides, so neprilysin inhibition would be expected to raise endogenous apelin exposure and prolong exogenous apelin. Mechanistically attractive in heart failure, but the combination has never been tested in humans, and the trade-off would be additive vasodilation and hypotension on top of sacubitril/valsartan's own blood-pressure-lowering effect.

    PMID 37956047 / PMC10757586

  • Vasopressin-axis drugs (desmopressin, tolvaptan and other vaptans)

    CautionTheoretical

    Apelin suppresses vasopressin release centrally and opposes V2-mediated water reabsorption in the collecting duct, so it would be expected to antagonize desmopressin and add to the aquaretic effect of vaptans, with a plausible risk of destabilizing sodium and water balance in anyone being managed for SIADH, diabetes insipidus or hyponatremia. The mechanism is well documented; the drug-drug pairing has never been studied, hence Theoretical.

    PMC8645901 (Front Endocrinol 2021); PMID 28620355 / PMC5450005

  • Loop and thiazide diuretics

    CautionLow

    Human apelin infusion increased natriuresis and free water clearance versus placebo, so combining it with diuretics could produce additive sodium and water loss and volume depletion - particularly relevant in the heart failure and CKD populations apelin is aimed at, who are typically already diuretic-treated. The natriuretic effect is human-demonstrated; the additive interaction itself is inferred, not observed.

    PMID 39402039 / PMC11473822

  • Tirzepatide and other incretin agonists

    CautionLow

    The only human test of an APJ agonist plus tirzepatide - the azelaprag STRIDES phase 2 - was terminated after transaminase elevations that were not seen in the tirzepatide-only arm. That is a real hepatic safety signal, but it involves an oral small-molecule APJ agonist, not apelin peptide, and whether the liability is on-target APJ agonism or specific to that chemotype is unresolved. For apelin peptide plus an incretin agonist there is no direct evidence at all, so this is class-level caution rather than an established moderate-severity interaction.

    BioAge Labs STRIDES discontinuation announcement, Dec 2024

  • Anti-angiogenic cancer therapy (bevacizumab, VEGF/VEGFR inhibitors)

    CautionTheoretical

    Preclinical work indicates apelin signalling contributes to escape from and resistance to anti-angiogenic therapy, with apelin inhibition improving response and reducing metastasis in animal models - so supplying exogenous apelin alongside VEGF-directed therapy is mechanistically the wrong direction. Entirely animal and cell data; never examined in patients.

    PMID 32087570 (review); PMC6685079 - identifier unverified

Known risks(5)

  • Extremely short plasma half-life limiting therapeutic utility

    Moderate

    Native apelin peptides have a plasma half-life of less than 8 minutes due to rapid enzymatic degradation by ACE2, neprilysin (NEP), and plasma kallikrein. This makes subcutaneous or oral delivery of native peptide impractical. Human studies have used intravenous and intra-arterial infusions, as well as intracoronary bolus administration, under research oversight.

  • Potential hepatotoxicity with synthetic apelin receptor agonists

    High

    The Phase 2 STRIDES trial of azelaprag (BGE-105, BioAge Labs) was discontinued in December 2024 after liver transaminase elevations were observed in 11 participants in azelaprag treatment groups, among 204 participants enrolled across all groups. No transaminase elevations occurred in the tirzepatide-only group. This hepatotoxicity signal has not been established for native apelin peptide but raises concerns about chronic apelin receptor agonism with small molecules.

  • Potential pro-tumorigenic effects via angiogenesis promotion

    Moderate

    Apelin promotes angiogenesis and has been shown to stimulate tumor growth and increase microvessel density in preclinical cancer models. High apelin expression is associated with elevated microvessel densities and poor overall survival in certain cancers. Apelin serum levels are positively correlated with BMI, and elevated apelin has been implicated in the association between obesity and increased breast cancer progression. The apelin/APJ pathway promotes peritoneal dissemination of ovarian cancer cells by regulating lipid metabolism.

  • Hypotension risk with acute administration

    Low-Moderate

    Apelin causes vasodilation and reduces systemic vascular resistance and blood pressure. In clinical studies, systemic apelin infusion at doses of 30-300 nmol/min caused measurable reductions in mean arterial pressure. While no serious hypotensive events were reported in published clinical trials, patients with pre-existing hypotension or those taking antihypertensive medications could be at increased risk.

  • Interaction with fluid balance and vasopressin regulation

    Low

    Apelin is a physiological antagonist of vasopressin (antidiuretic hormone), promoting aquaresis (free water clearance) and natriuresis (sodium excretion). While this may be beneficial in fluid overload states, it could theoretically exacerbate dehydration or electrolyte imbalances in susceptible individuals, particularly elderly patients or those with impaired renal function.

Drug interactions(7)

  • ACE inhibitors (enalapril, lisinopril, ramipril)

    Apelin upregulates ACE2, which converts angiotensin II to angiotensin-(1-7). ACE inhibitors block upstream ACE, reducing angiotensin II production. Combined use could produce additive blood pressure lowering and enhanced RAAS counter-regulation. Apelin's renoprotective effects in CKD patients are described as 'analogous to ACE inhibitors,' suggesting overlapping mechanisms.

  • Angiotensin II receptor blockers (ARBs: losartan, valsartan)

    The apelin receptor (APLNR) physically heterodimerizes with the AT1 receptor and exerts allosteric trans-inhibition of angiotensin II signaling. ARBs also block AT1R. Concurrent use could produce synergistic RAAS blockade with potential for excessive hypotension.

  • PDE5 inhibitors (sildenafil, tadalafil)

    The Brash et al. 2018 PAH study demonstrated that apelin's effects on reducing pulmonary vascular resistance and increasing cardiac output were accentuated in patients receiving concomitant PDE5 inhibitor therapy. This synergistic interaction could be therapeutically beneficial in PAH but may increase hypotension risk.

  • Mineralocorticoid receptor antagonists (spironolactone, eplerenone)

    Spironolactone has been shown to increase circulating apelin levels in patients with chronic systolic heart failure, suggesting interplay between aldosterone receptor blockade and the apelinergic system. Combined use may have additive cardiovascular and renal benefits.

  • Neprilysin inhibitors (sacubitril/valsartan)

    Neprilysin (NEP) is one of the primary enzymes that degrades apelin peptides. Sacubitril inhibits neprilysin, which could theoretically increase endogenous apelin levels and prolong exogenous apelin activity. This interaction may contribute to the cardiovascular benefits of sacubitril/valsartan (Entresto) in heart failure.

  • Vasopressin and vasopressin receptor agonists (desmopressin, terlipressin)

    Apelin is a physiological antagonist of vasopressin, opposing its antidiuretic effects and promoting free water clearance. Concurrent use with vasopressin agonists could reduce their antidiuretic efficacy. The vasopressin/apelin balance is critical for fluid homeostasis.

  • Antihypertensive agents (general)

    Apelin causes vasodilation and reduces mean arterial pressure and systemic vascular resistance. Additive hypotensive effects may occur when combined with any class of antihypertensive medication. Clinical studies have shown consistent blood pressure reduction with apelin infusion.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
60
Human Studies
12

Apelin's clinical evidence base is moderate-to-strong for acute cardiovascular hemodynamic effects and growing for renal and metabolic endpoints. The strongest human data come from Japp et al. 2010 (Circulation), an RCT demonstrating vasodilation and increased cardiac output in heart failure patients and healthy volunteers; Brash et al. 2018 (JACC), a double-blind crossover RCT in 19 PAH patients showing reduced pulmonary vascular resistance; Chapman et al. 2024 (Nature Communications), a double-blind RCT in 12 CKD patients that found short-term renal changes; and Gourdy et al. 2018, in which apelin improved insulin sensitivity in overweight men. For drug development, the AMG 986 first-in-human study (182 subjects, Cardiovascular Drugs and Therapy 2022) showed acceptable safety up to 650 mg/day. It produced no clinically meaningful hemodynamic effects in heart failure patients. Azelaprag (BGE-105) Phase 2 was discontinued in December 2024 due to hepatotoxicity signals. The major gaps are that no completed human trials target aging or longevity endpoints, that all native apelin infusion studies are acute (minutes to hours) with no chronic dosing data in humans, and that no apelin-targeting therapy has reached Phase 3.

Researched for(6)

Rated by confidence in the evidence

  • Cardiovascular protection: vasodilation, increased cardiac output, and blood pressure reduction

    Medium

    Human infusion trials show blood pressure and cardiac output shifts, not proven long-term protection.

    PMID 20385929 (Japp et al., Circulation 2010); PMID 39402039 / PMC11473822 (Nat Commun 2024)

  • Anti-aging and sarcopenia reversal via exerkine-mediated muscle regeneration

    Low

    Muscle regeneration shown in aged mice; human peptide evidence is lacking, correlational only.

    PMID 30061698 (Vinel et al., Nat Med 2018); BioAge Labs announcement of STRIDES discontinuation, Dec 2024

  • Pulmonary vascular improvement and reduced pulmonary vascular resistance in PAH

    High

    Randomized trial in PAH patients showed reduced pulmonary vascular resistance from a single infusion.

    PMID 29876530 / PMC5981010 (JACC Basic Transl Sci 2018)

  • Renoprotection: increased renal blood flow, natriuresis, and reduced proteinuria

    Medium

    Human RCT showed acute renal blood flow and natriuresis gains, not proven kidney protection.

    PMID 39402039 / PMC11473822 (Nat Commun 2024)

  • Metabolic improvement: enhanced insulin sensitivity and glucose uptake

    Medium

    Small human trial found improved insulin sensitivity at higher doses; not yet replicated.

    PMID 28681996 (Diabetes Obes Metab 2018). Removed: 'PMID 19861585 (Cell Metab 2009)' - the PMID/journal/year pairing does not reliably match the rodent apelin-glucose work it was cited for; the canonical rodent citation is Dray et al., Cell Metab 2008. Also removed NCT02033473 and NCT02724566, which could not be tied to this clamp study.

  • Counter-regulation of the renin-angiotensin-aldosterone system (RAAS)

    Low

    Mechanism and animal data support this; no human study has directly tested RAAS suppression.

    PMID 34385981 / PMC8359812 (LIT01-196, rodent); PMID 37956047 / PMC10757586 (Cardiovasc Res 2023 review); PMID 39402039 (human infusion physiology, indirect only)

Benefits(6)

  • Cardiovascular protection: vasodilation, increased cardiac output, and blood pressure reduction

    Japp et al. 2010 (Circulation, PMID 20385929) — Randomized, double-blind, placebo-controlled studies in 18 chronic heart failure patients, 6 coronary angiography patients, and 26 healthy volunteers: intrabrachial [Pyr1]apelin-13 caused forearm vasodilation preserved in heart failure patients; systemic infusion increased cardiac output and caused peripheral and coronary vasodilation. Chapman et al. 2024 (Nature Communications) — RCT in 12 CKD patients: apelin lowered mean arterial pressure, reduced systemic vascular resistance, and increased cardiac output.

  • Anti-aging and sarcopenia reversal via exerkine-mediated muscle regeneration

    Vinel et al. 2018 (Nature Medicine, PMID 30061698) — Demonstrated that apelin production induced by muscle contraction declines with age in humans and rodents; apelin- and APLNR-deficient mice developed dramatic age-associated sarcopenia; restoring apelin signaling enhanced muscle function by triggering mitochondriogenesis, autophagy, anti-inflammatory pathways in myofibers, and muscle stem cell regeneration. Identified apelin as both a diagnostic biomarker for early sarcopenia and a therapeutic target for age-related muscle weakness.

  • Pulmonary vascular improvement and reduced pulmonary vascular resistance in PAH

    Brash et al. 2018 (JACC: Basic to Translational Science, PMID 29876530) — Double-blind randomized crossover study in 19 PAH patients: intravenous [Pyr1]apelin-13 (10-100 nmol/min) reduced pulmonary vascular resistance and increased cardiac output without changing heart rate or systemic vascular resistance. Effects were accentuated in patients receiving concomitant PDE5 inhibitor therapy (sildenafil, tadalafil). Yang et al. 2019 (Br J Pharmacol, PMID 30710493) — Biased agonist MM07 was disease-modifying in the rat monocrotaline PAH model.

  • Renoprotection: increased renal blood flow, natriuresis, and reduced proteinuria

    Chapman et al. 2024 (Nature Communications, PMID 39402039) — First patient study of apelin in kidney disease: randomized, double-blind, placebo-controlled crossover in 12 CKD patients and 12 healthy controls. Apelin promoted urinary sodium excretion and free water clearance. In CKD patients, apelin reduced glomerular filtration rate, effective filtration fraction, and proteinuria with renoprotective effects analogous to ACE inhibitors. Supports chronic apelin receptor agonism for CKD.

  • Metabolic improvement: enhanced insulin sensitivity and glucose uptake

    Gourdy et al. 2018 (Diabetes, Obesity and Metabolism, PMID 28681996) — Apelin administration improved insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp. The apelinergic system influences glucose uptake, lipolysis, and fatty acid oxidation via AMPK/eNOS and PI3K/Akt pathways. Altered apelin levels are observed in obesity and type 2 diabetes, positioning the apelin system as a potential therapeutic target for metabolic disorders.

  • Counter-regulation of the renin-angiotensin-aldosterone system (RAAS)

    Siddiquee et al. 2013 (Br J Pharmacol, PMC3594671) — APJ inhibits AT1 receptor via allosteric trans-inhibition through receptor heterodimerization, reducing orthosteric AT1 agonist efficacy. Apelin upregulates ACE2 transcription, increasing conversion of angiotensin II to the beneficial Ang-(1-7) peptide, providing cardioprotective and renoprotective effects. This counter-regulatory mechanism has implications for hypertension, heart failure, and age-related cardiovascular decline.

Key studies(5)

  1. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure

    Randomized, double-blind, placebo-controlled study18 heart failure patients, 6 coronary angiography patients, 26 healthy volunteersAcute infusion (30-300 nmol/min, 5-min infusions)

    Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE

    Circulation

    2010

    Landmark human study establishing apelin's cardiovascular pharmacology. Intrabrachial [Pyr1]apelin-13 caused forearm vasodilation in both heart failure patients and controls. Critically, vasodilation to apelin was preserved in heart failure patients even when acetylcholine-mediated vasodilation was impaired. Systemic infusion increased cardiac output and caused peripheral and coronary vasodilation. Studies were well tolerated with no serious adverse events or ECG changes.

  2. The exerkine apelin reverses age-associated sarcopenia

    Preclinical with human correlation dataMultiple mouse cohorts (apelin-KO, APLNR-KO, aged wild-type); human plasma samplesChronic apelin supplementation over weeks in aged mice

    Vinel C, Lukjanenko L, Batut A, Dray C, Waget A, Arce-Suarez M, Bonnafous S, Garret C, Viber C, Saez E, Mazelin L, Burcelin R, Casteilla L, Penicaud L, Feige JN, Rando TA, Dang PM, Valet P, Pradere JP

    Nature Medicine

    2018

    Transformative study for the aging field. Demonstrated that apelin production declines with age in humans and rodents and is positively associated with the beneficial effects of exercise in older persons. Apelin- and APLNR-deficient mice developed dramatic age-associated sarcopenia. Restoring apelin signaling in aged mice enhanced muscle function by triggering mitochondriogenesis, autophagy, and anti-inflammatory pathways in myofibers while enhancing regenerative capacity by targeting muscle stem cells. Identified apelin as both a diagnostic biomarker for early sarcopenia and a pharmacological target.

  3. Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

    Double-blind, randomized crossover study19 PAH patientsThree 5-minute IV infusions of ascending doses (10, 30, 100 nmol/min)

    Brash L, Barnes GD, Brewis MJ, Church AC, Gibbs SJ, Howard LSGE, Jayasekera G, Johnson MK, McGlinchey N, Onorato J, Simpson J, Stirrat C, Thomson S, Watson G, Wilkins MR, Xu C, Welsh DJ, Newby DE, Peacock AJ

    JACC: Basic to Translational Science

    2018

    Systemic [Pyr1]apelin-13 infusion caused a significant reduction in pulmonary vascular resistance and increased cardiac output in PAH patients without changing heart rate or systemic vascular resistance. Effects were accentuated in the subgroup of patients receiving concomitant PDE5 inhibition (sildenafil, tadalafil). Concluded that apelin agonism represents a novel therapeutic target for PAH. Study was well tolerated.

  4. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study

    Randomized, double-blind, placebo-controlled crossover12 CKD patients, 12 healthy controlsAcute infusion (1 and 30 nmol/min [Pyr1]apelin-13)

    Chapman FA, Melville V, Godden E, Morrison B, Bruce L, Maguire JJ, Davenport AP, Newby DE, Dhaun N

    Nature Communications

    2024

    First patient study investigating apelin as a therapeutic target in kidney disease. Apelin lowered mean arterial pressure and systemic vascular resistance, increased cardiac output and renal blood flow, and promoted urinary sodium excretion and free water clearance. In CKD patients specifically, apelin reduced GFR, effective filtration fraction, and proteinuria — renoprotective effects analogous to ACE inhibitors. Supports development of chronic apelin receptor agonism for CKD. Registered as NCT03956576.

  5. A first-in-human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients

    Phase 1b, randomized, double-blind, placebo-controlled182 subjects (116 AMG 986/healthy, 38 placebo; 20 AMG 986/HF, 8 placebo)Single-dose and multiple-dose escalation (oral and IV)

    Winkle P, Goldsmith S, Koren MJ, Lepage S, Hellawell J, Trivedi A, Tsirtsonis K, Abbasi SA, Kaufman A, Troughton R, Voors A, Hulot JS, Donal E, Kazemi N, Neutel J

    Cardiovascular Drugs and Therapy

    2022

    First-in-human evaluation of a synthetic oral apelin receptor agonist. AMG 986 demonstrated acceptable safety up to 650 mg/day. No dose-related safety signals were clinically significant. However, clinically meaningful pharmacodynamic effects in heart failure patients were not observed. Changes in ejection fraction and stroke volume suggested additional studies are needed to define optimal dosing. Registered as NCT03276728.

Regulation & availability

Why researchers look at it

A landmark 2018 Nature Medicine study identified apelin as an "exerkine" that declines with age, and showed that restoring it in aged mice reversed muscle wasting by reactivating mitochondrial production and stem cell regeneration. Over 3,000 publications exist, and human trials demonstrate acute blood-pressure and cardiac-output effects, and one small CKD trial found short-term renal changes; long-term kidney protection remains unproven. If a stable oral apelin agonist is developed, it could address cardiovascular aging, sarcopenia, and metabolic decline through a single pathway.

FDA status
Apelin peptide has no FDA regulatory status — it is not an approved drug, it is not under active FDA review, and it is not listed as a bulk drug substance under FDA's 503A/503B compounding framework. No Investigational New Drug (IND) application for native apelin peptide is publicly listed. Synthetic apelin receptor agonists have undergone FDA-regulated clinical trials: AMG 986 (Amgen) completed Phase 1b under IND with acceptable safety but insufficient efficacy in heart failure (NCT03276728). Azelaprag/BGE-105 (BioAge Labs) entered Phase 2 (STRIDES trial) for obesity in combination with tirzepatide but was discontinued in December 2024 after hepatotoxicity signals (liver transaminase elevations in 11 of 204 participants). BMS-986224 (Bristol-Myers Squibb) completed preclinical evaluation as an orally bioavailable APJ agonist but its current clinical development status is unclear. No apelin-targeting compound has reached Phase 3 or received an FDA approval pathway designation (Breakthrough Therapy, Fast Track, etc.).
WADA status
Apelin is not specifically named on the 2026 WADA Prohibited List. However, the WADA Prohibited List includes broad categories that could potentially encompass apelin-related substances. Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) prohibits 'other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching.' Given apelin's demonstrated effects on muscle regeneration, angiogenesis, and metabolic regulation, it could theoretically fall under this catch-all provision. Additionally, any substance with identical biological effects to prohibited substances can be covered under the WADA principle of 'substances with similar chemical structure or similar biological effects.' Athletes should consult their Anti-Doping Organization and check the Global Drug Reference Online (GlobalDRO) for definitive guidance before using any apelin-related substance.
Prescribability
Apelin is NOT approved as a prescription medication in any country. It is not FDA-approved and has not received regulatory approval from the EMA, PMDA, or any other major drug regulatory authority. Apelin is not included in the FDA's bulk drug substances evaluation list (neither Category 1 nor Category 2) and therefore is not available through US 503A or 503B compounding pharmacies for clinical use. No compounding pharmacy formulations exist for patient administration. There is no legitimate pathway for a physician to prescribe native apelin peptide for a patient at this time. Synthetic small-molecule apelin receptor agonists (AMG 986, BMS-986224, azelaprag/BGE-105) have been evaluated in clinical trials but none has received marketing authorization.
Availability
Synthetic small-molecule apelin receptor agonists (AMG 986, BMS-986224, azelaprag) are investigational compounds available only within registered clinical trial frameworks. Apelin peptide has been administered to humans exclusively in the context of investigator-initiated clinical studies at academic medical centers (University of Edinburgh, University of Glasgow) under appropriate regulatory oversight.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(15)

  1. 1993
    APJ receptor cloned from human genomic library as an orphan GPCR with 31% homology to AT1 receptor
  2. 1998
    Apelin identified as endogenous ligand for APJ by Tatemoto et al. from bovine stomach extracts; named 'APJ Endogenous LIgaNd'
  3. 2010
    Japp et al. publish first comprehensive human cardiovascular study of apelin in Circulation (PMID 20385929)
  4. 2013-2014
    Elabela/Toddler identified as second endogenous ligand for the apelin receptor by Chng et al. and Pauli et al.
  5. 2015
    IUPHAR officially recommends renaming APJ to 'apelin receptor' and recognizing Elabela as second endogenous ligand
  6. 2017-09
    Amgen initiates Phase 1b trial of AMG 986 (oral apelin receptor agonist) for heart failure (NCT03276728)
  7. 2018
    Vinel et al. publish landmark exerkine/sarcopenia study in Nature Medicine; Brash et al. publish PAH hemodynamics study in JACC: BTS
  8. 2019
    Yang et al. demonstrate MM07 (biased apelin receptor agonist) is disease-modifying in PAH rat model
  9. 2021
    BMS-986224 (Bristol-Myers Squibb) preclinical evaluation published: orally bioavailable APJ agonist with potent selectivity (Kd = 0.3 nM)
  10. 2022-04
    AMG 986 first-in-human results published: acceptable safety in 182 subjects but no clinically meaningful effects in heart failure
  11. 2022-04
    BioAge Labs doses first cohort in Phase 1b trial of azelaprag (BGE-105) for muscle aging indications
  12. 2023-10
    BioAge Labs announces Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity in collaboration with Lilly's Chorus organization
  13. 2024-10
    Chapman et al. publish CKD study in Nature Communications: first patient study showing apelin renoprotective effects (NCT03956576)
  14. 2024-12
    BioAge Labs discontinues STRIDES Phase 2 trial after liver transaminase elevations in 11 azelaprag-treated participants among 204 total trial participants
  15. 2025
    BioAge Labs announces plans to share updated azelaprag development strategy; next-generation APJ agonists in preclinical development

Sources & FAQs

Research sources(13)

Frequently asked questions(6)

What is apelin and what does it do in the body?

Apelin is a naturally occurring peptide produced throughout the body, particularly in the heart, lungs, kidneys, brain, adipose tissue, and skeletal muscle. It acts by binding to the apelin receptor (APLNR/APJ), a G-protein-coupled receptor. Apelin causes blood vessels to dilate (reducing blood pressure), increases the heart's pumping strength (positive inotropy), promotes new blood vessel formation (angiogenesis), regulates fluid balance by opposing vasopressin, improves insulin sensitivity and glucose metabolism, and supports muscle maintenance during exercise. It exists in several active forms: apelin-36, apelin-17, apelin-13, and [Pyr1]apelin-13, with the pyroglutamated form being the most abundant in human blood and the most potent.

Why is apelin relevant to aging and longevity research?

Apelin levels decline naturally with age in both humans and rodents. A landmark 2018 Nature Medicine study showed that apelin functions as an 'exerkine' — a molecule released during exercise that mediates exercise's anti-aging benefits on muscle. When researchers restored apelin signaling in aged mice, it reversed age-related muscle weakness (sarcopenia) by stimulating mitochondrial biogenesis, autophagy, anti-inflammatory pathways, and muscle stem cell regeneration. Additionally, mice lacking the apelin gene develop accelerated cardiac aging with progressive loss of heart contractility. The apelin system's decline with age and its role in counteracting the renin-angiotensin system (which becomes overactive with aging) makes it a compelling target for anti-aging interventions.

Can I take apelin as a supplement or medication?

No. Apelin is not available as a supplement, medication, or compounding pharmacy formulation. Native apelin peptides have an extremely short half-life (under 8 minutes in blood) due to rapid degradation by enzymes including ACE2, neprilysin, and plasma kallikrein, making them impractical for self-administration. The peptide has been administered in controlled research using intravenous and intra-arterial infusions and intracoronary bolus administration. Synthetic oral apelin receptor agonists (like AMG 986 and azelaprag) have been tested in clinical trials but none is approved or commercially available.

What is the difference between apelin and Elabela/Toddler?

Apelin and Elabela (also called Toddler) are both endogenous peptide ligands for the same receptor (APLNR/APJ), but they are structurally distinct peptides with different expression patterns. Apelin was discovered first in 1998, while Elabela was identified independently by two groups in 2013-2014. Elabela is a 54-amino acid peptide (cleaved to 32 amino acids) that shares no sequence homology with apelin. Elabela is critical during embryonic development, particularly for cardiovascular formation — this explains why knocking out the receptor gene causes lethal cardiovascular failure in embryos, while knocking out apelin alone does not. Together they form a spatiotemporal dual-ligand system controlling apelin receptor signaling.

How does apelin interact with the renin-angiotensin system?

Apelin is an endogenous counter-regulator of the renin-angiotensin-aldosterone system (RAAS). The apelin receptor (APLNR) physically heterodimerizes with the angiotensin II type 1 receptor (AT1R), and through allosteric trans-inhibition, APJ reduces AT1R signaling — blocking both angiotensin II binding and its downstream effects. Additionally, apelin upregulates ACE2, which converts the harmful angiotensin II into beneficial angiotensin-(1-7). This dual mechanism means apelin effectively opposes the vasoconstriction, sodium retention, inflammation, and fibrosis driven by angiotensin II. However, apelin is itself degraded by ACE2 and neprilysin, creating a tight negative feedback loop.

What happened with clinical trials of apelin receptor agonist drugs?

Several synthetic apelin receptor agonists have reached clinical trials with mixed results. Amgen's AMG 986 completed Phase 1b in 182 subjects (2022) with acceptable safety across the doses tested but failed to show meaningful hemodynamic effects in heart failure patients. BioAge Labs' azelaprag (BGE-105) entered Phase 2 (STRIDES trial) for obesity in combination with tirzepatide targeting adults 55+ with obesity, but was discontinued in December 2024 after 11 of 204 participants developed liver transaminase elevations. The biased agonist MM07 (University of Edinburgh) was terminated in Phase 1. Bristol-Myers Squibb's BMS-986224 showed strong preclinical results as an orally bioavailable APJ agonist. The field remains active, with researchers exploring next-generation compounds with improved receptor selectivity and safety profiles.